^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AFNT-211

    i
    Other names: AFNT-211
    Company:
    Affini-T Therap
    Drug class:
    TCR modulator, KRAS G12V inhibitor
    Related drugs:
    9ms
    Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Affini-T Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12V • KRAS G12 • HLA-A*11
    |
    AFNT-211
    1year
    Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor (clinicaltrials.gov)
    P1/2, N=100, Not yet recruiting, Affini-T Therapeutics, Inc.
    New P1/2 trial • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12V • KRAS G12 • HLA-A*11
    |
    AFNT-211